NEW YORK--(BUSINESS WIRE)--PIN Pharma, Inc., today announced final results of a first-in-human clinical trial of its novel immunomodulating agent PIN-2 in subjects with advanced solid tumors. This was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results